Safety of acid-suppressing drugs

Digestive Diseases and Sciences

Volumn 40, Issue 2 Supplement, 1995, Pages

  Smallwood, Richard A ^{a,b,c,d,e,f,g,h,i}   Berlin, Roger G ^{a,b,c,d,e,f,g,h,i}   Castagnoli, Neal ^{a,b,c,d,e,f,g,h,i}   Festen, Henk P M ^{a,b,c,d,e,f,g,h,i}   Hawkey, Christopher J ^{a,b,c,d,e,f,g,h,i}   Lam, S K ^{a,b,c,d,e,f,g,h,i}   Langman, Michael J S ^{a,b,c,d,e,f,g,h,i}   Lundborg, Per ^{a,b,c,d,e,f,g,h,i}   Parkinson, Andrew ^{a,b,c,d,e,f,g,h,i}  

^a HEIDELBERG REPATRIATION HOSPITAL   (Australia)

^b MERCK RESEARCH LABORATORIES   (United States)

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^h ASTRAZENECA R AND D   (Sweden)

ⁱ UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

antisecretory drugs; drug toxicity; drug drug interactions; drugs in pregnancy; gastric ADH; P 450 induction; P 450 inhibition; surveillance

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CALCIUM ANTAGONIST; CIMETIDINE; CYTOCHROME P450; ENPROSTIL; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPRAMINE; LIDOCAINE; MISOPROSTOL; NIZATIDINE; OMEPRAZOLE; PARACETAMOL; PHENAZONE; PHENYLBUTAZONE; PHENYTOIN; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; RANITIDINE; ROXATIDINE; THEOPHYLLINE; WARFARIN;

CONFERENCE PAPER; DRUG SAFETY; DRUG TOXICITY; GYNECOMASTIA; HEPATITIS; HUMAN; IMMUNE RESPONSE; INOTROPISM; NEUROTOXICITY; PEPTIC ULCER; PREGNANCY; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ACID SECRETION;

FEMALE; GASTRIC ACID; HISTAMINE H2 ANTAGONISTS; HUMAN; OMEPRAZOLE; PREGNANCY;

EID: 0028864984     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/BF02214872     Document Type: Article

References (265)

1. Hepatic effects of drugs used in the treatment of peptic ulcer disease
2. Effects of antacids on the clinical pharmacokinetics of drugs. An update
3. Hepatotoxic and hepatoprotective potential of histamine (H2)-receptor antagonists
4. Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential
5. Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions
6. Ranitidine interactions: A literature review
7. The drug interaction potential of ranitidine: An update
8. Pharmacokinetic interaction of cimetidine
9. Drug interactions involving cimetidine-mechanisms, documentation, implications
10. Histamine H2-antagonists drug interactions in perspective: Mechanistic concepts and clinical implications
11. Effect of cimetidine and ranitidine on cardiovascular drugs
12. Clinically important adverse effects and drug interactions with H2-receptor antagonists: An update
13. Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism
14. Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam
15. Acetaminophen interaction with cimetidine and ranitidine: A critical analysis of the literature
16. Influence of cimetidine on pharmacokinetics of propranolol
17. Effect of cimetidine and ranitidine on the pharmacokinetics and the antihypertensive action of nifedipine
18. The effect of ranitidine and cimetidine on single dose diltiazem pharmacokinetics
19. Influence of cimetidine on verapamil kinetics and dynamics
20. Increased toxicity and reduced clearance of lidocaine by cimetidine
21. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man
22. Slow omeprazole metabolisers are also poor S-mephenytoin hydroxylators
23. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man
24. Theophylline pharmacokinetics—effect of continuous versus intermittent cimetidine IV infusion
25. The interaction of omeprazole with rat liver cytochrome P-450-mediated monooxygenase reactions in vitro and in vivo
26. Omeprazole: Effects on oxidative drug metabolism
27. Omeprazole: Pharmacology, pharmacokinetics and interactions
28. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro
29. Effect of omeprazole and cimetidine on plasma diazepam levels
30. Effects of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole
31. Stereoselective interaction of omeprazole with warfarin in healthy men
32. A study of the interaction between omeprazole and phenytoin in epileptic patients
33. Oral phenytoin pharmacokinetics during omeprazole therapy
34. Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo
35. Effect of omeprazole on theophylline metabolism in healthy subjects
36. Omeprazole treatment does not affect the metabolism of caffeine
37. Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol
38. Propranolol steady-state pharmacokinetics are unaltered by omeprazole
39. Lack of effect of omeprazole on the disposition of lignocaine and its active metabolite in healthy subjects
40. Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole
41. No interaction between omeprazole and cyclosporine
42. Drug interaction studies with omeprazole—a review
43. Influence of gastric acidity on the bioavailability of digoxin
44. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population
45. Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450
46. Inhibitors of cytochrome P-450s and their mechanism of action
47. Interactions of nitrogen heterocycles with cytochrome P-450 and monooxygenase activity
48. Inhibition of cytochrome P-450 enzymes
49. Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes
50. Spectral and kinetic studies of the interaction of imidazole antifungal agents with microsomal cytochromes P-450
51. Inhibition of testosterone biosynthesis in testicular microsomes by various imidazole drugs. Comparative study with ketoconazole
52. High magnitude hepatic cytochrome P-450 induction by an N-substituted imidazole antimycotic, clotrimazole
53. Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents
54. Substrate interactions with cytochrome P-450
55. Evidence of induction of hepatic microsomal cytochrome P-450 by cimetidine: Binding and kinetic studies
56. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450
57. Purification and characterization of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylase, two prototypes for genetic polymorphism in oxidative drug metabolism
58. Purification and characterization of liver microsomal cytochromes P450: Electrophoresis, spectral, catalytic and immunochemical properties and inducibility of eight enzymes isolated from rats treated with phenobarbital or β-nephthoflavone
59. Induction of cytochrome P4501A genes (CYP1A) by omeprazole in the human alimentary tract
60. Characterisation of theophylline metabolism by human liver microsomes
61. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man
62. Human cytochrome P450PA (P450 1A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines
63. Increase of cytochrome P4501A2 activity by omeprazole: Evidence by the13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin
64. Omeprazole and the induction of human cytochrome P-450. A response to concerns about potential adverse effects
65. In vivo interactions between H2-receptor antagonists and ethanol metabolism in man and in rats
66. Effects of cimetidine on the elimination and actions of ethanol
67. Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists
68. Effects of cimetidine on gastric alcohol dehydrogenase activity and blood ethanol levels
69. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism
70. Effects of H2-receptor antagonists on ethanol metabolism in Japanese volunteers
71. The effect of cimetidine on the metabolism and effects of alcohol
72. The effect of the administration of H2-receptor blockers on alcohol kinetics and psychophysical fitness
73. Is ethanol metabolism affected by oral administration of cimetidine and ranitidine at therapeutic doses?
74. Influence of cimetidine and ranitidine on ethanol pharmacokinetics
75. The effect of ranitidine, cimetidine or famotidine on low-dose post-prandial alcohol absorption
76. Cimetidine and alcohol consumption
77. Reply to “Cimetidine and alcohol consumption.”
78. Effects of various concomitant medications on gastric alcohol dehydrogenase and the first-pass metabolism of ethanol
79. Histamine-2 receptor antagonists do not alter serum ethanol levels in fed, nonalcoholic men
80. Lack of effect of omeprazole, cimetidine and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers
81. Ranitidine, cimetidine, famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken after an evening meal
82. Effect of omeprazole on gastric first-pass metabolism of ethanol
83. Ranitidine has no effect on postbreakfast ethanol absorption
84. Histamine receptors
85. Histamine and noradrenaline decrease calcium-activated potassium conductase in hippocampal pyramidal cells
86. CSF concentrations of ranitidine
87. Cerebrospinal fluid concentration of famotidine
88. No detectable concentrations of oxmetidine but measurable concentrations of cimetidine in cerebrospinalfluid (CSF) during multiple dose treatment
89. Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion
90. Dose and serum concentration relationship in cimetidine-associated mental confusion
91. Cimetidine distribution in human serum, tissue and cerebrospinal fluid
92. Effects of histamine H1- and H2-receptor antagonists on the activity of serotonin-containing neurons in the dorsal raphe
93. Cimetidine-induced prolactin release: Possible involvement of GABA-ergic system
94. Adverse reactions and interactions with H2-receptor antagonists
95. Use of ranitidine, without mental confusion, in patients with renal failure
96. Cimetidine-induced mania
97. A case-report of cimetidine-induced depressive syndrome
98. Cimetidine: Does neurotoxicity occur? Report of 3 cases
99. Cimetidine-induced mania in depressed patients
100. Ranitidine and confusion
101. Ranitidine-associated hallucinations
102. The comparative efficiency of cimetidine and ranitidine in controlling gastric pH in critically ill patients
103. Ranitidine and cimetidine in stress-ulcer prophylaxis: a comparative multicenter study
104. Focus on misoprostol: Review of worldwide safety data
105. Side effects of anti-ulcer prostaglandins: An overview of the worldwide clinical experience
106. Neurosensory adverse effects after phenylbutazone and misoprostol combined treatment
107. Safety profile of omeprazole. Adverse events with short-term treatment
108. The clinical safety of omeprazole
109. Acute interstitial nephritis due to omeprazole
110. Renal function and cimetidine
111. Effects of cimetidine, ranitidine and antacid on renal function
112. Cimetidine-induced interstitial nephritis with response to prednisolone therapy
113. Cimetidine-induced acute interstitial nephritis
114. Immunologic studies in cimetidine-induced nephropathy and polymyositis
115. Cimetidine-induced renal failure
116. Effect of histamine H2-receptor antagonist ranitidine on renal brush border and basolateral membranes
117. Active proton secretion and potassium absorption in the rabbit outer medullary collecting duct: Functional evidence for H-K-ATPase
118. Ouabain-insensitive K-adenosine triphosphatase in distal nephron segments of the rabbit
119. Characterization of K-ATPase activity in distal nephron stimulation by potassium depletion
120. H-K-ATPase immunoreactivity in cortical and outer medullary collecting duct
121. Omeprazole, a gastric proton pump inhibitor: Lack of effect on renal handling of electrolytes and urinary acidification
122. Cimetidine an immunomodular
123. Cime-tidine as an immunomodulator: Chronic mucocutaneous candidiasis as a model
124. Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia
125. Ranitidine and cimetidine in renal transplantation: A clinical trial
126. Cimetidine and renal allograft rejection
127. Cimetidine and polymyositis
128. Immunomodulatory properties of cimetidine in ARC patients
129. Effects of cimetidine and ranitidine on delayed-type hypersensitivity
130. Effects of famotidine (YM-11170), an H2-receptor antagonist, on in vivo immediate and delayed type hypersensitivity reactions and antibody formation
131. Mechanism for histamine-H2-receptor induced cell cycle changes in the bone marrow stem cell
132. Mechanism of ranitidine associated anemia
133. Haematological adverse effects of histamine H2-receptor antagonists
134. Agranulocytosis and ranitidine
135. Bone marrow suppression associated with cimetidine
136. Side effects of histamine2-receptor antagonists
137. Continuing evaluation of the safety of medicine
138. Cimetidineinduced neutropenia. A possible dose related phenomenon
139. The use of ranitidine in bone marrow transplantation. A review of 223 cases
140. Bone marrow hypoplasia during intensive care: Bone marrow culture studies implicating ranitidine in the suppression of haemopoiesis
141. Cimetidine-associated thrombocytopenia
142. Cimetidine and thrombocytopenia
143. Hypothalamic-pituitary-gonadal dysfunction in men using cimetidine
144. Effect of cimetidine on gonadal function in man
145. An investigation of the effect of oral ranitidine treatment on hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal function in male and female volunteers
146. An evaluation of the anti-androgen effects associated with H2-antagonist therapy
147. Long-term treatment with cimetidine does not essentially affect the hypothalamic-pituitary-gonadal axis in man
148. Ranitidine does not affect gonadal function in man
149. Cimetidine, a histamine H2-receptor antagonist, occupies androgen receptors
150. A comparative study of the effects of ranitidine and cimetidine on carbohydrate tolerance, growth hormone secretion and the hypothalamic-pituitary-gonadal axis in man
151. Effects of cimetidine on prolactin, LH and sex steroid secretion in male and female volunteers
152. Endocrine effects of acute and chronic cimetidine administration
153. Effects of cimetidine on pituitary function: Alterations in hormone secretion profiles
154. Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine
155. Cimetidine blocks testosterone synthesis
156. The acute and long term effect of the H2-receptor antagonists cimetidine and ranitidine on the pituitary-gonadal axis in man
157. The effect of oral cimetidine on the basal and stimulated values of prolactin, thyroid stimulating hormone, follicle stimulating hormone and luteinizing hormone
158. Effects of short-and long-term administrations of famotidine and ranitidine on some pituitary, sexual and thyroid hormones
159. A pharmacokinetic profile of nizatidine in man
160. Cimetidine induced impotence and breast changes in patients with gastric hypersecretory states
161. Gynaecomastia associated with cimetidine
162. Endocrine adverse effects of omeprazole
163. Comparison between dose-responses of prolactin, thyroid stimulating hormone and growth hormone to two different histamine H2-receptor antagonists in normal men
164. Variations in serum prolactin following cimetidine treatment for peptic ulcer disease
165. Cimetidine and serum prolactin
166. Prolactin responses to cimetidine
167. Stimulation of prolactin-release by intravenous cimetidine: A dose response study
168. Cimetidine, a H2-antihistamine, stimulates prolactin secretion in man
169. Central nervous system mediated stimulation of prolactin secretion by cimetidine, a histamine H2-receptor antagonist: Impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia
170. Effect of 800 mg cimetidine and 300 mg ranitidine on serum prolactin
171. Hyperprolactinemia: Ranitidine revised adverse effect
172. Effects of two histamine H2-receptor blockingdrugs on basal levels of gonadotrophins, prolactin, testosterone and oestradiol-17β during treatment of duodenal ulcer in male patients
173. Effect of the new H2-receptor antagonist ranitidine on plasma prolactin levels in duodenal ulcer patients
174. The effect of histamine stimulation and H2-receptor inhibition on the pituitary prolactin and ACTH release and on cortisol secretion in human males
175. Effect of intravenous ranitidine on serum prolactin (PRL): Evidence for a sex difference
176. Properties of famotidine in relation to safety
177. Endocrine functions in man after long-term famotidine therapy
178. Famotidine effects on prolactin, growth hormone, and thyrotropin pituitary secretion in man
179. Effects of the oral administration of famotidine on basal prolactin serum levels
180. Effect of histamine H2-receptor antagonists on vasopressin and aldosterone secretion
181. Hyperosmolar non-ketotic diabetes and cimetidine
182. Doseresponse study of omeprazole on meal-stimulated gastric acid secretion and gastrin release
183. Vierwochige Omeprazolgabe: Einfluss auf Saureverhalten und basale Hormonspiegel
184. Inhibition by omeprazole of adrenocortical response to ACTH: Clinical studies and experiments on bovine adrenal cortex in vitro
185. The effects of omeprazole on endocrine function in man
186. Effect of intravenous omeprazole on basal and stimulated cortisol and 11-deoxycortisol levels in healthy subjects
187. Effect of single dose of omeprazole on the gastrointestinal peptide response to food
188. Cholestatische Hepatose unter Cimetidine
189. Cimetidine hepatitis
190. Cimetidine cholestatic jaundice in children
191. Cimetidine-induced hepatitis. Electron microscopic observations and clinical pattern of liver injury
192. Hepatitis following cimetidine administration
193. Cimetidine
194. Bridging hepatic necrosis associated with cimetidine
195. Cimetidine-induced liver injury. Report of three cases
196. Cimetidine hepatitis
197. Long-term follow-up study of cimetidine
198. H2-antagonists and hepatitis
199. Chronic toxicity study of ranitidine hydrochloride orally administered in rat
200. Possible ranitidine hepatitis
201. Possible ranitidine hepatoxicity
202. Hepatitis associated with ranitidine
203. Effects of H2-blocking agents on hepatocytes in vitro: Correlation with potential for causing hepatic disease in patients
204. Chronic active hepatitis associated with cimetidine
205. Inhibitory effect of cimetidine on liver regeneration after two-thirds hepatectomy in rats
206. Ranitidine as an inhibitor of liver regeneration
207. Effects of H2-receptor antagonists on liver after partial hepatectomy or carbon tetrachloride induced hepatic injury
208. Prophylaxis of upper gastrointestinal bleeding with cimetidine in patients undergoing partial hepatectomy
209. Reduction of liver blood flow and propranolol metabolism by cimetidine
210. Ranitidine also reduces liver blood flow
211. Effect of famotidine on hepatic hemodynamics and peptic ulcer
212. Effect of cimetidine on portal hypertension in cirrhotic patients
213. The effect of ranitidine on the plasma clearance and hepatic extraction of indocyanine green in patients with chronic liver disease
214. The effect of chronic treatment with gastric antisecretory drugs on functional liver plasma flow
215. Effects of cimetidine and ranitidine on splanchnic hemodynamics in patients with chronic liver disease
216. Rapid healing of duodenal ulcers with omeprazole: Doubleblind dose-comparative trial
217. Omeprazole: No evidence for frequent hepatic reactions
218. Safety aspects of omeprazole
219. Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse — a randomized double-blind study with weekly endoscopic assessment
220. Overview of clinical safety with misoprostol
221. Cimetidine and adverse reactions: A meta analysis of randomised clinical trials of short term therapy
222. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases
223. Safety of nizatidine in clinical trials conducted in the USA and Europe
224. Prevention of NSAID-induced gastric ulcer with the synthetic prostaglandin, misoprostol — a multicentre, double-blind, placebo-controlled trial
225. Cimetidine in the treatment of acute alcoholic pancreatitis
226. Cimetidine-induced acute pancreatitis
227. Inotropic effects of histamine in human myocardium: differentiation between positive and negative components
228. Negative inotropic effect of some H2 receptor antagonists on the isolated human atria
229. Haemodynamic effects of cimetidine or ranitidine iv
230. Cimetidine and bradycardia
231. Ranitidine-induced bradycardia
232. Life threatening arrhythmias and intravenous cimetidine
233. Cimetidine induced arrhythmias
234. Troubles de la conduction auriceoventriculaire sous ranitidine intra-veineuse
235. Negative inotropic effects of famotidine
236. Haemodynamic effects of famotidine and cimetidine in critically ill patients
237. Influence of histamine receptors on basal left ventricular contractile tone in humans: Assessment using the H2-receptor antagonist famotidine and the beta adrenoceptor antagonist esmolol as pharmacologic probes
238. Urticaria from ranitidine
239. Hyperpyrexia associated with intravenous cimetidine therapy
240. Fever after cimetidine and ranitidine
241. Immunologic studies of cimetidine-induced nephropathy and polymyositis
242. Recurrent myalgias associated with cimetidine
243. First-degree atrioventricular block in a young duodenal ulcer patient treated with a standard oral dose of ranitidine
244. The treatment of gastrointestinal disease in pregnancy
245. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus
246. The Committee on FDA-Related Matters. GI drug column. The use of gastrointestinal drugs during pregnancy and lactation
247. Prenatal and neonatal exposure to cimetidine results in gonadal and sexual dysfunction in adult males
248. Characterization and development of cimetidine as a histamine H2 receptor antagonist
249. Prenatal and neonatal exposure of male rat pups to cimetidine but not ranitidine adversely affects subsequent adult sexual functioning
250. Cimetidine in pregnancy: Apparent transient liver impairment in the newborn
251. Cimetidine, antacids, and pulmonary aspiration
252. Preliminary report on the use of ranitidine as an antacid in obstetrics
253. Oral ranitidine in labour
254. Cimetidine and gastric cancer; preliminary report from post marketing surveillance study
255. Post marketing surveillance of the safety of cimetidine: 12 months mortality
256. Post marketing surveillance of the safety of cimetidine: 12 months morbidity report
257. Post marketing surveillance of the safety of cimetidine: mortality during second, third and fourth years of follow up
258. Review: Post marketing surveillance of the safety of cimetidine—the problems of data interpretation
259. Post marketing surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus
260. Antisecretory drugs and gastric cancer
261. Cancer occurrence in a cohort of patients treated with cimetidine
262. Low clearance of cimetidine across the human placenta